Sabby Management’s Abeona Therapeutics ABEO Stock Holding History

Sabby Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,414	Closed	-$197K	–	88
2019 Q4	$197K	Buy	+2,414	New	+$170K	0.05%	50
2018 Q2	–	Sell	-520	Closed	-$187K	–	140
2018 Q1	$187K	Buy	+520	New	+$193K	0.02%	123
2016 Q3	–	Sell	-10,800	Closed	-$637K	–	308
2016 Q2	$637K	Sell	10,800 -2,564	-19%	-$175K	0.03%	197
2016 Q1	$855K	Buy	13,364 +1,364	+11%	+$90.3K	0.04%	166
2015 Q4	$1.01M	Sell	12,000 -1,628	-12%	-$163K	0.06%	179
2015 Q3	$1.38M	Buy	13,628 +7,238	+113%	+$961K	0.06%	203
2015 Q2	$808K	Sell	6,390 -25,124	-80%	-$3.77M	0.03%	229
2015 Q1	$2.47M	Sell	31,514 -8,110	-20%	-$653K	0.1%	128
2014 Q4	$3.47K	Buy	+39,624	New	+$3.55M	0.11%	89

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's ABEO Position: Q1 2020 in Review

Sabby Management sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 2,414 shares — an estimated $197K sold.

Sabby Management first reported a position in ABEO in Q4 2014 and held it in 9 quarters. The position peaked at $2.47M in Q1 2015. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

Sabby Management reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
Sabby Management sold 2,414 Abeona Therapeutics shares in Q1 2020, an estimated $197K.
Sabby Management first reported a position in Abeona Therapeutics in Q4 2014 and held it in 9 quarters.
Sabby Management's Abeona Therapeutics position peaked at $2.47M in Q1 2015.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Sabby Management's 13F filing for Q1 2020, filed 15 May 2020.